Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. - Wikidata - wikimedia - TriplyDB

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

http://www.wikidata.org/entity/Q37505818

about

The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.The psychosis spectrum in Parkinson disease.Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.Perioperative management of Parkinson's disease.Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.Treatment of Sleep Dysfunction in Parkinson's Disease.Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes.Prevalence of and indications for antipsychotic use in Parkinson's disease.Structural and functional alterations of the heart in Parkinson's disease.Parkinson's disease psychosis: presentation, diagnosis and management.

P2860

Q26738456-DCE2944F-D1CD-436F-98AB-DC735C0B0126 Q26745661-41E21EBE-E64E-4327-AC72-92D46B02EB68 Q33810051-912686C0-36EE-4747-9767-6D9525161F7E Q37548320-84C97BEE-3F98-42A1-A7F6-C456F1B067AB Q38768169-2AF26B8B-BB98-402C-A1BD-B059AB386CB1 Q38894971-DB109F72-766D-4189-8D6B-27F574745FC2 Q38966013-E0DB8EB2-2008-4BFC-AA44-7183103254A7 Q39004255-E674F82D-E5F6-490E-8A8C-95EC0FA09E2C Q39342961-425DDA94-7BD5-4126-BAE1-CB8DC0AD0A35 Q43375910-D53F396C-E326-4694-BF2D-DA9296C29E1E Q47094610-CE1FBBE5-0F7B-44FC-BE55-607707B45D13 Q48349028-BB581B47-B5F9-41B0-AD96-CD5767502200 Q50066781-8C26FC47-FE96-4F1D-903E-588FB97471EA Q51781286-C47D9FCA-3284-49FA-9D04-B6687D7F7E49

P2860

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

http://www.wikidata.org/entity/Q37505818

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@en

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@nl

type

label

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@en

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@nl

prefLabel

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@en

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@nl

P1433

Q37505818-D879B28E-3720-4E13-A2E4-0BEC493BBD89

P1476

Q37505818-DA4209A6-0216-45B6-8C5E-AF838AEF6102

P2093

Q37505818-1982A0DE-E8F2-4F9D-A479-EC078B2CBD5D

Q37505818-318AF876-7CCB-4EAE-9412-E8D20758FD6F

Q37505818-94CE48D9-3B4A-44E6-9306-7424F9E95DA1

Q37505818-BBB88047-152B-4069-89AF-D3B1DC56099D

Q37505818-E4DC1604-5817-4B4A-9534-B33C199A36D1

Q37505818-E53A768F-AF98-478F-A760-0EC14F40116B

P2860

Q37505818-188E6584-B621-48B5-ACB2-EBE3E1E572EA

Q37505818-1BCA1949-ACAF-4314-99BA-C20C6FA5F4C5

Q37505818-1C028743-B28F-4C63-9A49-7B10A8DED6F3

Q37505818-258A20A9-86DA-4453-AF99-DCFB3486603E

Q37505818-295B192C-E8E3-415F-A9EB-1688FCA1057E

Q37505818-2A970445-06F6-451E-922A-BEA1E8C2F3F5

Q37505818-2B4F9DE8-787C-4B82-B395-A5B9FBFE6C15

Q37505818-2BA3D30E-507A-46BF-90B2-0598C93F5CF0

Q37505818-32D48E4B-BAD6-4B9B-9464-EBB00E141620

Q37505818-3584DAB8-17FC-4A72-842D-9B3A6649E094

P304

Q37505818-67BA2A6A-4A6A-40DE-80AD-6521BF160DB7

P31

Q37505818-6A142DEE-D71D-425C-ACCB-2EE6C69838A4

P356

Q37505818-604063FC-B488-4212-BBCC-F01198ED3245

P407

Q37505818-B6D5495B-4B51-4457-BFC1-8C07360BDE0E

P433

Q37505818-3651DF44-23B0-4822-A42E-B17C6FD1E25B

P478

Q37505818-C3465205-D119-4DC1-945D-1FDCB426828F

P50

Q37505818-22F2497B-644B-4302-AADA-31475C9A9A14

Q37505818-4AB6414B-3CC3-458F-B439-FC3D46F86144

P577

Q37505818-26B06581-581A-423F-A175-CC2E97448A55

P698

Q37505818-6E1DB07F-8160-41C3-82D2-B8E724751EB2

P921

Q37505818-E35E0125-B538-4024-A35A-3767EB7E8C53

P932

Q37505818-D05725CB-94E0-4C40-9B41-2215A1A2D1A1

P356

JAMANEUROL.2016.0031

P1433

P1476

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

@en

P2093

Barbara Stanislawski

http://www.w3.org/2001/XMLSchema#string

Claire Chiang

http://www.w3.org/2001/XMLSchema#string

Eugenia Mamikonyan

http://www.w3.org/2001/XMLSchema#string

Helen C Kales

http://www.w3.org/2001/XMLSchema#string

Hyungjin Myra Kim

http://www.w3.org/2001/XMLSchema#string

Jayne Wilkinson

http://www.w3.org/2001/XMLSchema#string

P2860

Nonpharmacologic management of behavioral symptoms in dementia

Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel

Assessment and management of behavioral and psychological symptoms of dementia

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

Parkinson's disease: the quintessential neuropsychiatric disorder

The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.

Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

P304

535-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2016.0031

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Weintraub

Connie Fernández-Cid Marras

P577

2016-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26999262

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5157923

http://www.w3.org/2001/XMLSchema#string